Compare AbCellera Biologics Inc (ABCL) vs AT&T Inc. (T) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

AT&T (T) trades at $21.06, up 2.38% today but remains near multi-year lows amid competitive pressures. The stock shows bearish technical signals with key support at $20, while fundamentals reveal strong profitability with a 16.94% net margin and attractive valuation at a P/E of 6.93. Recent earnings beats and a 5.4% dividend yield provide support, but SpaceX competition concerns dominate sentiment.

Outlook: Undervalued with significant upside to the $29.50 consensus target, but high debt and Starlink disruption risks temper near-term optimism. Investment case hinges on execution in fiber/wireless growth against stiff competition, with cash flow stability supporting the dividend.